Pluronic F127 "nanoarmor" for stabilization of Cowpea mosaic virus immunotherapy.

Authors:
Shin MD; Jung E; Moreno-Gonzalez MA; Ortega-Rivera OA; Steinmetz NF.

Journal:
Bioeng Transl Med

Publication Year: 2023

DOI:
10.1002/btm2.10574

PMCID:
PMC10771553

PMID:
38193118

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Bioeng Transl Med

Abbreviation: Bioeng Transl Med

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Engineering, Biomedical

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
4D-CT deformable image registration using unsupervised recursive cascaded full-resolution residual …
Xu L; Jiang P; Tsui T and 4 more (2023) - Transparency Score: 3/6
Activation of NR1H3 attenuates the severity of septic myocardial injury by inhibiting NLRP3 inflamm…
Deng C; Liu Q; Zhao H and 9 more (2023) - Transparency Score: 3/6
Adipose-derived stem cells enriched with therapeutic mRNA TGF-β3 and IL-10 synergistically promote …
Wang W; Chen L; Zhang Y and 5 more (2023) - Transparency Score: 4/6
Adjustable extracellular matrix rigidity tumor model for studying stiffness dependent pancreatic du…
Zhang H; Chen J; Hu X and 2 more (2023) - Transparency Score: 3/6
A drug-selectable acoustic reporter gene system for human cell ultrasound imaging.
Howells AR; Welch PJ; Kim J and 3 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"data s1."

Code Sharing
Evidence found in paper:

"CONFLICT OF INTEREST STATEMENT The authors declare the following competing financial interest(s): Dr. Steinmetz is a co‐founder of, has equity in, and has a financial interest with Mosaic ImmunoEngineering Inc. Dr. Steinmetz serves as Director, Board Member, and Acting Chief Scientific Officer, and paid consultant to Mosaic. The other authors declare no potential conflict of interest."

Evidence found in paper:

"This work was funded in part by the following grants from the NIH (R01‐CA274640 and R01‐HL137674 to N.F.S.). M.D.S. was supported in part by CBI training program NIH T32GM112584."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025